Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Clinical manifestations of homozygote allele carriers in Huntington disease.

Cubo E, Martinez-Horta SI, Santalo FS, Descalls AM, Calvo S, Gil-Polo C, Muñoz I, Llano K, Mariscal N, Diaz D, Gutierrez A, Aguado L, Ramos-Arroyo MA; European HD Network.

Neurology. 2019 Mar 13. pii: 10.1212/WNL.0000000000007147. doi: 10.1212/WNL.0000000000007147. [Epub ahead of print]

PMID:
30867264
2.

Clinical manifestations of intermediate allele carriers in Huntington disease.

Cubo E, Ramos-Arroyo MA, Martinez-Horta S, Martínez-Descalls A, Calvo S, Gil-Polo C; European HD Network.

Neurology. 2016 Aug 9;87(6):571-8. doi: 10.1212/WNL.0000000000002944. Epub 2016 Jul 8.

PMID:
27402890
3.

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.

Moss DJH, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators; REGISTRY investigators, Holmans P, Jones L, Tabrizi SJ.

Lancet Neurol. 2017 Sep;16(9):701-711. doi: 10.1016/S1474-4422(17)30161-8. Epub 2017 Jun 20. Erratum in: Lancet Neurol. 2017 Sep;16(9):683.

PMID:
28642124
4.

Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course.

Squitieri F, Gellera C, Cannella M, Mariotti C, Cislaghi G, Rubinsztein DC, Almqvist EW, Turner D, Bachoud-Lévi AC, Simpson SA, Delatycki M, Maglione V, Hayden MR, Donato SD.

Brain. 2003 Apr;126(Pt 4):946-55.

PMID:
12615650
5.

Age-at-onset in Huntington disease.

Orth M, Schwenke C.

PLoS Curr. 2011 Jul 29;3:RRN1258. doi: 10.1371/currents.RRN1258.

6.

Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.

Huntington Study Group PHAROS Investigators, Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, Siemers E, Tanner C, Mallonee W, Suter G, Dubinsky R, Gray C, Nance M, Bundlie S, Radtke D, Kostyk S, Baic C, Caress J, Walker F, Hunt V, O'Neill C, Chouinard S, Factor S, Greenamyre T, Wood-Siverio C, Corey-Bloom J, Song D, Peavy G, Moskowitz C, Wesson M, Samii A, Bird T, Lipe H, Blindauer K, Marshall F, Zimmerman C, Goldstein J, Rosas D, Novak P, Caviness J, Adler C, Duffy A, Wheelock V, Tempkin T, Richman D, Seeberger L, Albin R, Chou KL, Racette B, Perlmutter JS, Perlman S, Bordelon Y, Martin W, Wieler M, Leavitt B, Raymond L, Decolongon J, Clarke L, Jankovic J, Hunter C, Hauser RA, Sanchez-Ramos J, Furtado S, Suchowersky O, Klimek ML, Guttman M, Sethna R, Feigin A, Cox M, Shannon B, Percy A, Dure L, Harrison M, Johnson W, Higgins D, Molho E, Nickerson C, Evans S, Hobson D, Singer C, Galvez-Jimenez N, Shannon K, Comella C, Ross C, Saint-Hilaire MH, Testa C, Rosenblatt A, Hogarth P, Weiner W, Como P, Kumar R, Cotto C, Stout J, Brocht A, Watts A, Eberly S, Weaver C, Foroud T, Gusella J, MacDonald M, Myers R, Fahn S, Shults C.

JAMA Neurol. 2016 Jan;73(1):102-10. doi: 10.1001/jamaneurol.2015.2736.

PMID:
26569098
7.

Homozygotes and heterozygotes for ciliary neurotrophic factor null alleles do not show earlier onset of Huntington's disease.

Rubinsztein DC, Leggo J, Chiano M, Korn S, Dodge A, Norbury G, Rosser E, Craufurd D.

Neurology. 1997 Sep;49(3):890-2.

PMID:
9305364
8.

What is the impact of education on Huntington's disease?

López-Sendón JL, Royuela A, Trigo P, Orth M, Lange H, Reilmann R, Keylock J, Rickards H, Piacentini S, Squitieri F, Landwehrmeyer B, Witjes-Ane MN, Jurgens CK, Roos RA, Abraira V, de Yébenes JG; European HD Network.

Mov Disord. 2011 Jul;26(8):1489-95. doi: 10.1002/mds.23385. Epub 2011 Mar 22.

PMID:
21432905
9.

Intermediate CAG Repeats in Huntington's Disease: Analysis of COHORT.

Ha AD, Beck CA, Jankovic J.

Tremor Other Hyperkinet Mov (N Y). 2012;2. pii: tre-02-64-287-4. doi: 10.7916/D8FF3R2P. Epub 2012 Feb 2.

10.

Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.

Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR; TRACK-HD Investigators.

Lancet Neurol. 2013 Jul;12(7):637-49. doi: 10.1016/S1474-4422(13)70088-7. Epub 2013 May 9.

PMID:
23664844
11.

Cognitive decline in Huntington's disease expansion gene carriers.

Baake V, Reijntjes RHAM, Dumas EM, Thompson JC; REGISTRY Investigators of the European Huntington's Disease Network, Roos RAC.

Cortex. 2017 Oct;95:51-62. doi: 10.1016/j.cortex.2017.07.017. Epub 2017 Aug 3.

PMID:
28843844
12.

Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175.

Menalled LB, Kudwa AE, Miller S, Fitzpatrick J, Watson-Johnson J, Keating N, Ruiz M, Mushlin R, Alosio W, McConnell K, Connor D, Murphy C, Oakeshott S, Kwan M, Beltran J, Ghavami A, Brunner D, Park LC, Ramboz S, Howland D.

PLoS One. 2012;7(12):e49838. doi: 10.1371/journal.pone.0049838. Epub 2012 Dec 20.

13.

Clinical and genetic characteristics in patients with Huntington's disease from China.

Yang J, Chen K, Wei Q, Chen Y, Cao B, Burgunder JM, Shang HF.

Neurol Res. 2016 Oct;38(10):916-20. doi: 10.1080/01616412.2016.1214555. Epub 2016 Jul 29.

PMID:
27483361
14.

Homozygote of spinocerebellar Ataxia type 3 correlating with severe phenotype based on analyses of clinical features.

Shang XJ, Xu HL, Yang JS, Chen PP, Lin MT, Qian MZ, Lin HX, Chen XP, Chen YC, Jiang B, Chen YJ, Chen WJ, Wang N, Zhou ZM, Gan SR.

J Neurol Sci. 2018 Jul 15;390:111-114. doi: 10.1016/j.jns.2018.04.026. Epub 2018 Apr 18.

PMID:
29801869
15.

Identification of extreme motor phenotypes in Huntington's disease.

Braisch U, Hay B, Muche R, Rothenbacher D, Landwehrmeyer GB, Long JD, Orth M; REGISTRY Investigators of the European Huntington's Disease Network and COHORT Investigators of the Huntington Study Group.

Am J Med Genet B Neuropsychiatr Genet. 2017 Apr;174(3):283-294. doi: 10.1002/ajmg.b.32514. Epub 2016 Nov 21.

PMID:
27868347
16.

Weight loss in Huntington disease increases with higher CAG repeat number.

Aziz NA, van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T; EHDI Study Group, Roos RA.

Neurology. 2008 Nov 4;71(19):1506-13. doi: 10.1212/01.wnl.0000334276.09729.0e.

PMID:
18981372
17.

Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS.

Killoran A, Biglan KM, Jankovic J, Eberly S, Kayson E, Oakes D, Young AB, Shoulson I.

Neurology. 2013 May 28;80(22):2022-7. doi: 10.1212/WNL.0b013e318294b304. Epub 2013 Apr 26.

18.

COMT Val158Met Polymorphism Modulates Huntington's Disease Progression.

de Diego-Balaguer R, Schramm C, Rebeix I, Dupoux E, Durr A, Brice A, Charles P, Cleret de Langavant L, Youssov K, Verny C, Damotte V, Azulay JP, Goizet C, Simonin C, Tranchant C, Maison P, Rialland A, Schmitz D, Jacquemot C, Fontaine B, Bachoud-Lévi AC; French Speaking Huntington Group.

PLoS One. 2016 Sep 22;11(9):e0161106. doi: 10.1371/journal.pone.0161106. eCollection 2016.

19.

Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study.

Paulsen JS, Long JD, Ross CA, Harrington DL, Erwin CJ, Williams JK, Westervelt HJ, Johnson HJ, Aylward EH, Zhang Y, Bockholt HJ, Barker RA; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.

Lancet Neurol. 2014 Dec;13(12):1193-201. doi: 10.1016/S1474-4422(14)70238-8. Epub 2014 Nov 3.

20.

Biallelic mutations in huntington disease: A new case with just one affected parent, review of the literature and terminology.

Uhlmann WR, Peñaherrera MS, Robinson WP, Milunsky JM, Nicholson JM, Albin RL.

Am J Med Genet A. 2015 May;167A(5):1152-60. doi: 10.1002/ajmg.a.37009. Epub 2015 Mar 3.

PMID:
25736541

Supplemental Content

Support Center